ReviewTrends in cardiovascular medicine2014
Hyperlipidemia, tissue factor, coagulation, and simvastatin.
Review in Trends in cardiovascular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Effects of products designed to modulate the gut microbiota on hyperlipidaemia.European journal of nutrition · 2019Pooled it
- Metabolic phenotyping of sepsis in large multicenter cohorts: identification of a reproducible high-risk subgroup.Lipids in health and disease · 2026Article
- Simvastatin Alleviates ConA-Induced Autoimmune Hepatitis by Inhibiting CD4Inflammation · 2026Article
- Nonlinear association of a body shape index and hyperlipidemia: an American population-based cross-sectional study.Annals of medicine · 2025Article
- Research on the mechanism of sea buckthorn leaf Fu tea in the treatment of hyperlipidemia.Heliyon · 2024Article
- Developing a Biomimetic 3D Neointimal Layer as a Prothrombotic Substrate for a Humanized In Vitro Model of Atherothrombosis.Biomimetics (Basel, Switzerland) · 2024Article
- Untargeted and Targeted Metabolomics Reveal the Active Peptide ofMolecules (Basel, Switzerland) · 2023Article
- Review
- NLRP3 Inflammasome Overactivation in Patients with Aneurysmal Subarachnoid Hemorrhage.Translational stroke research · 2023Article
- Nephrotic Syndrome and Statin Therapy: An Outcome Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- Investigation of Hyperlipidemia Associated with Increased Levels of Oxidized Low-Density Lipoproteins and 8-Hydroxy-2´-Deoxyguanosine.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Efficacy and safety of tai chi for hyperlipidaemia: a protocol for systematic review and meta-analysis.BMJ open · 2022Article
- Unraveling the molecular mechanisms of hyperlipidemia using integrated lncRNA and mRNA microarray data.Experimental and therapeutic medicine · 2022Article
- Danshen Decoction in the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis Protocol of Randomized Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Effectiveness of managing suspected metastasis using plasma D-dimer testing in gastric cancer patients.American journal of cancer research · 2022Article
- Hawthorn fruit acid consumption attenuates hyperlipidemia-associated oxidative damage in rats.Frontiers in nutrition · 2022Article
- Active Peptide AR-9 FromFrontiers in pharmacology · 2022Article
- Risk Factors for Gastric Cancer-Associated Thrombotic Diseases in a Han Chinese Population.BioMed research international · 2021Article
- AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis.Journal of thrombosis and thrombolysis · 2020Article
- Role of Nrf2 and Its Activators in Cardiocerebral Vascular Disease.Oxidative medicine and cellular longevity · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hyperlipidemia affects millions of people worldwide and is a major risk factor for cardiovascular disease. People with hyperlipidemia have elevated levels of serum cholesterol and an increased risk of thrombosis. Studies have suggested that oxidized lipoproteins, such as oxidized low-density lipoprotein (oxLDL), contribute to the development of a pro-thrombotic state. In this review, we discuss our recent studies demonstrating a role for hematopoietic cell-derived tissue factor (TF) expression in the activation of coagulation and increased thrombosis associated with hyperlipidemia. In addition, we investigated the effect of simvastatin on TF expression and coagulation. We found that simvastatin reduced leukocyte TF expression, TF⁺ microparticles, and coagulation. These results and earlier studies suggest that the anti-coagulant activity of statins is due, in part, to their ability to reduce monocyte TF expression in patients with cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.